Brief: Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline And Continued Innovative Potential Of Existing Portfolio At ESMO 2026
13/10/2026 11:46
BRIEF-Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline And Continued Innovative Potential Of Existing Portfolio At ESMO 2026 Oct 13 (Reuters) - Merck & Co Inc MRK.N:
MERCK SHOWCASES FIRST-TIME PIVOTAL PHASE 3 RESULTS FROM ONCOLOGY PIPELINE AND CONTINUED INNOVATIVE POTENTIAL OF EXISTING PORTFOLIO AT ESMO 2026
MERCK & CO - SAC-TMT PHASE 3 TRIAL SHOWS IMPROVED SURVIVAL IN ENDOMETRIAL CANCER
Source text: ID:nBw2r7xHTa
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines